

## BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 20, 2017 /[PRNewswire](#)/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 10<sup>th</sup> Annual Biotech Showcase, being held on January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.

### 10<sup>th</sup> Annual Biotech Showcase Presentation Details

Date: Monday, January 8, 2018  
Time: 4:00pm Pacific Time  
Location: Hilton San Francisco Union Square, Yosemite B  
Webcast: <https://goo.gl/pvpjbc>

### Meetings

BrainStorm senior management will also be hosting institutional investor and partnering meetings at the Biotech Showcase conference or through the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with BrainStorm Cell Therapeutics, investors can reach out through the Biotech Showcase one-on-one partnering system (<https://goo.gl/a1XZB3>) or [register](#) on the online system managed by the Company's US investor relations firm, [LifeSci Advisors, LLC](#), or make a request via e-mail at [Access@LifeSciAdvisors.com](mailto:Access@LifeSciAdvisors.com).

### About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company's website at [www.brainstorm-cell.com](http://www.brainstorm-cell.com).

### CONTACTS

Corporate:  
Uri Yablonka  
Chief Business Officer  
BrainStorm Cell Therapeutics Inc.  
Phone: 646-666-3188  
[uri@brainstorm-cell.com](mailto:uri@brainstorm-cell.com)

Investors:  
Michael Rice  
LifeSci Advisors LLC  
Phone: 646-597-6979  
[mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)

Media:  
Matt Middleman, M.D.  
LifeSci Public Relations, LLC  
Phone: 646-627-8384  
[matt@lifescipublicrelations.com](mailto:matt@lifescipublicrelations.com)

View original content with multimedia: <http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-the-10th-annual-biotech-showcase-300573776.html>



SOURCE BrainStorm Cell Therapeutics Inc.

---

<https://ir.brainstorm-cell.com/2017-12-20-BrainStorm-Cell-Therapeutics-to-Present-at-the-10th-Annual-Biotech-Showcase>